| ²é¿´: 156 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö £¬µã»÷ÕâÀï½øÐв鿴 | ||
paper½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖú ¼ìË÷ºÅ ÔÚÏßµÈ
|
|
| SPARCL1 suppresses metastasis in prostate cancer |
» ²ÂÄãϲ»¶
Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
²ÄÁϹ¤³Ìר˶ 348·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸ÄÏ´ó£¬0703»¯Ñ§£¬·ÖÊý336£¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
322Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
0703»¯Ñ§µ÷¼Á
ÒѾÓÐ4È˻ظ´
»¯Ñ§µ÷¼Á
ÒѾÓÐ4È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
ÉúÎïѧµ÷¼Á
ÒѾÓÐ3È˻ظ´
¹¤¿Æ0856Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
baiyuefei
°æÖ÷ (ÎÄѧ̩¶·)
·çÑ©
- Ó¦Öú: 4642 (¸±½ÌÊÚ)
- ¹ó±ö: 46.969
- ½ð±Ò: 658104
- É¢½ð: 11616
- ºì»¨: 995
- ɳ·¢: 81
- Ìû×Ó: 69424
- ÔÚÏß: 13328.1Сʱ
- ³æºÅ: 676696
- ×¢²á: 2008-12-18
- ÐÔ±ð: GG
- רҵ: ºÏ³ÉÒ©Îﻯѧ
- ¹ÜϽ: Óлú½»Á÷
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
paper: ½ð±Ò+20, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2016-05-09 12:50:44
lazy½õϪ: LS-EPI+1, ¸ÐлӦÖú£¡ 2016-05-09 13:01:28
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
paper: ½ð±Ò+20, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2016-05-09 12:50:44
lazy½õϪ: LS-EPI+1, ¸ÐлӦÖú£¡ 2016-05-09 13:01:28
|
SPARCL1 suppresses metastasis in prostate cancer ×÷Õß:Xiang, YZ (Xiang, Yuzhu)[ 1,2 ] ; Qiu, QC (Qiu, Qingchao)[ 1,10,11 ] ; Jiang, M (Jiang, Ming)[ 3,4,12 ] ; Jin, RJ (Jin, Renjie)[ 3,4 ] ; Lehmann, BD (Lehmann, Brian D.)[ 6 ] ; Strand, DW (Strand, Douglas W.)[ 3,4 ] ; Jovanovic, B (Jovanovic, Bojana)[ 7 ] ; DeGraff, DJ (DeGraff, David J.)[ 3,4 ] ; Zheng, Y (Zheng, Yi)[ 1,2 ] ; Yousif, DA (Yousif, Dina A.)[ 1 ] ; Simmons, CQ (Simmons, Christine Q.)[ 1 ] ; Case, TC (Case, Thomas C.)[ 3,4 ] ; Yi, J (Yi, Jia)[ 1 ] ; Cates, JM (Cates, Justin M.)[ 8 ] ; Virostko, J (Virostko, John)[ 9 ] ; He, XS (He, Xiusheng)[ 10,11 ] ; Jin, XB (Jin, Xunbo)[ 2 ] ; Hayward, SW (Hayward, Simon W.)[ 3,4,7 ] ; Matusik, RJ (Matusik, Robert J.)[ 3,4,7 ] ; George, AL (George, Alfred L., Jr.)[ 1,5 ] ; Yi, YJ (Yi, Yajun)[ 1,5 ] ¸ü¶àÄÚÈݸüÉÙÄÚÈÝ Òþ²Ø ResearcherID ºÍ ORCID²é¿´ ResearcherID ºÍ ORCID ×÷Õß ResearcherID ORCID ºÅ Cates, Justin D-5927-2014 https://orcid.org/0000-0002-7336-5196 Strand, Douglas https://orcid.org/0000-0002-0746-927X MOLECULAR ONCOLOGY ¾í: 7 ÆÚ: 6 Ò³: 1019-1030 DOI: 10.1016/j.molonc.2013.07.008 ³ö°æÄê: DEC 2013 ²é¿´ÆÚ¿¯ÐÅÏ¢ MOLECULAR ONCOLOGY ³ö°æÉÌ ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND ISSN: 1574-7891 eISSN: 1878-0261 Ñо¿ÁìÓò Oncology ÕªÒª Purpose: Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level. Experimental design: Based on a pattern of reduced expression in human prostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo. Results: SPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models. Conclusions: We present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. ¹Ø¼ü´Ê ×÷Õ߹ؼü´Ê rostate cancer; Gene expression signature; Meta-analysis; Metastasis; SPARCL1 function in vivo KeyWords Plus:EXTRACELLULAR-MATRIX PROTEIN; MESENCHYMAL TRANSITION; MATRICELLULAR PROTEIN; SECRETED-PROTEIN; BONE METASTASIS; TUMOR-CELLS; EXPRESSION; HEVIN; STATISTICS; CARCINOMA ×÷ÕßÐÅÏ¢ ͨѶ×÷ÕßµØÖ·: Yi, YJ (ͨѶ×÷Õß) Vanderbilt Univ, Div Med Genet, 536A Light Hall,2215 Garland Ave, Nashville, TN 37232 USA. ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University µØÖ·: [ 1 ] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 2 ] Shandong Univ, Prov Hosp, Minimally Invas Urol Ctr, Jinan 250021, Peoples R China ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Shandong University [ 3 ] Vanderbilt Univ, Vanderbilt Prostate Canc Ctr, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 4 ] Vanderbilt Univ, Dept Urol Surg, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 5 ] Vanderbilt Univ, Inst Integrat Gen, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 6 ] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 7 ] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 8 ] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 9 ] Vanderbilt Univ, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Vanderbilt University [ 10 ] Univ South China, Canc Res Inst, Hengyang 421001, Peoples R China ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ University of South China [ 11 ] Univ South China, Human Morphol Ctr, Hengyang 421001, Peoples R China ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ University of South China [ 12 ] Nantong Univ, Med Res Ctr, Sch Med, Lab Nucl Receptors & Canc Res, Nantong, Peoples R China ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ Nantong University µç×ÓÓʼþµØÖ·:yuzhuxiang@gmail.com; qingchao.qiu@vanderbilt.edu; ming.jiang.1@ntu.edu.cn; re-njie.jin@Vanderbilt.edu; brian.d.lehmann@Vanderbilt.edu; doug.strand@Vanderbilt.edu; bojana.jo-vanovic@Vanderbilt.edu; david.degraff@Vanderbilt.edu; milozhengyi@gmail.com; dina.a.yousif@Vanderbilt.edu; christine.simmons@Vanderbilt.Edu; tom.case@Vanderbilt.edu; jyi5@uthsc.edu; justin.m.cates@Vanderbilt.edu; jack.virostko@vanderbilt.edu; hexiusheng@hotmail.com; jin-xunbo@163.com; simon.hayward@vanderbilt.edu; robert.matusik@vanderbilt.edu; al.george@vanderbilt.edu; yajun.yi@vanderbilt.edu »ù½ð×ÊÖúÖÂл »ù½ð×ÊÖú»ú¹¹ ÊÚȨºÅ Howard Temin Award from the National Cancer Institute at the National Institutes of Health CA114033 American Cancer Society-Institutional Research Grant IRG-58-009-51 IRG-58-009-53 Vanderbilt Clinical and Translational Science Awards (CTSA) from National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH) UL1 RR024975 CRC1838 National Cancer Institute 4R01-CA076142-14 American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship ²é¿´»ù½ð×ÊÖúÐÅÏ¢¹Ø±Õ»ù½ð×ÊÖúÐÅÏ¢ Grant Support: This work was supported in part by a Howard Temin Award from the National Cancer Institute at the National Institutes of Health (CA114033 to YY), American Cancer Society-Institutional Research Grant (#IRG-58-009-51 and #IRG-58-009-53), and the Vanderbilt Clinical and Translational Science Awards (CTSA) UL1 RR024975 from National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH), (CRC1838 to YY), and the National Cancer Institute (4R01-CA076142-14 to RJM). DJD was supported by the American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship. ³ö°æÉÌ ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND Àà±ð / ·ÖÀà Ñо¿·½Ïò:Oncology Web of Science Àà±ð:Oncology ÎÄÏ×ÐÅÏ¢ ÎÄÏ×ÀàÐÍ:Article ÓïÖÖ:English Èë²ØºÅ: WOS:000328176400003 PubMed ID: 23916135 ISSN: 1574-7891 eISSN: 1878-0261 ÆäËûÐÅÏ¢ IDS ºÅ: 268NA Web of Science ºËÐĺϼ¯ÖÐµÄ "ÒýÓõIJο¼ÎÄÏ×": 50 Web of Science ºËÐĺϼ¯ÖÐµÄ "±»ÒýƵ´Î": 2 Ó°ÏìÒò×Ó 5.331 5.669 2014 5 Äê JCR® Àà±ð Àà±ðÖеÄÅÅÐò JCR ·ÖÇø ONCOLOGY 28/211 Q1 Êý¾ÝÀ´×ÔµÚ 2014 °æ Journal Citation Reports® |
2Â¥2016-05-09 12:42:28













»Ø¸´´ËÂ¥
rostate cancer; Gene expression signature; Meta-analysis; Metastasis; SPARCL1 function in vivo